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Approximately 50% of human malignancies carry p53 mutations, which makes it a potential antigenic target for cancer
immunotherapy. Adoptive transfer with p53-speciﬁc cytotoxic T-lymphocytes (CTL) and CD4+ T-helper cells eradicates p53-
overexpressing tumors in mice. Furthermore, p53 antibodies and p53-speciﬁc CTLs can be detected in cancer patients, indicating
that p53 is immunogenic. Based on these results, clinical trials were initiated. In this paper, we review immunological and
clinical responses observed in cancer patients vaccinated with p53 targeting vaccines. In most trials, p53-speciﬁc vaccine-induced
immunological responses were observed. Unfortunately, no clinical responses with signiﬁcant reduction of tumor-burden have
occurred. We will elaborate on possible explanations for this lack of clinical eﬀectiveness. In the second part of this paper, we
summarizeseveralimmunopotentiatingcombinationstrategies suitableforclinicaluse.In ouropinion,future p53-vaccine studies
should focus on addition of these immunopotentiating regimens to achieve clinically eﬀective therapeutic vaccination strategies
f o rc a n c e rp a t i e n t s .
1.Introduction
Despite recent progress in surgical, chemotherapeutic, and
radiotherapeutic approaches, cancer is still diﬃcult to treat
and cure, especially in patients with advanced stage of dis-
ease. Therefore, new therapeutic strategies are required. One
of the new treatment strategies is immunotherapy targeting
tumor-associated antigens (TAA).
Mutation of the p53 tumor-suppressor gene is a frequent
event in human oncogenesis. The role of the p53 gene has
been reviewed extensively by Vogelstein and Vousden [1–3].
P53 mutations found in tumors were shown to abrogate the
regulatory function of p53 on the cell cycle. Moreover, many
mutations lead to an increased half-life of the otherwise
rapidly degraded p53 protein and thereby to accumulation
of this protein in cells [4]. Other tumor suppressor genes
often lose their expression after mutation, but the point
mutated p53 protein is often more stable and therefore
overexpressed in tumor cells [5, 6]. p53 degradation can
also be promoted directly through binding to viral proteins
or deletions promoting presentation for T cell recognition
[1, 2].
CD8+ cytotoxic T-lymphocytes (CTLs) are the most
important eﬀector cells for antitumor immune responses.
They recognize TAA-derived peptides that are processed
and presented on the tumor cell surface in association with
major histocompatibility complex (MHC) class I molecules,
leading to killing of tumor cells [7]. Processing of the
intracellular p53 protein by the proteasome will result in
presentation of p53-derived peptides in the context of MHC
class I molecules at the tumor cell surface. CD4+ T-helper
(Th) cells play an important role in orchestrating and2 Journal of Biomedicine and Biotechnology
sustainingthelocalimmuneattackbyCTL[8,9].Incontrast,
CD4+FoxP3+ regulatory T cells (Tregs) impede antitumor
immunity by inhibiting CTL activation [10, 11].
The search forwidely expressed tumorantigensastargets
f o rM H Cc l a s sIr e s t r i c t e dC T L si so fg r e a ti m p o r t a n c e
for the development of T cell-mediated immunotherapy of
cancer. As persistent overexpression of p53 or induced T cell
presentation is present in ∼50% of a wide variety of cancers,
a large group of patients would beneﬁt from p53 directed
immunotherapy.
Since p53 is a self-antigen expressed at low levels in
normal cells, immunogenic tolerance might hinder the use
of wild type p53 as a tumor antigen for immunotherapeutic
approaches. Moreover, the idea of targeting a nonmutated
wild-type p53 gene with a vaccine may be counterintuitive.
So far induction of p53-speciﬁc CTL and Th cells with the
capacity to eradicate p53-presenting tumors without induc-
ing clinical nor immunopathological damage to normal tis-
sue has beenobserved in diﬀerentmouse models, despite the
fact that wild-type p53 is expressed in normal tissue [12–14].
This tumor selectivity could be explained by the increased
p53 protein expression resulting from p53 mutation [13].
Alternatively, insuﬃcient antigen display in normal tissues
by the MHC class I molecule in combination with lack of
orpropercostimulationanddownregulatory chemokineand
cytokine conditions might protect against the destruction
by the potentially autoreactive wild-type p53-speciﬁc CTL
[15, 16]. Consequently, wild-type p53-speciﬁc CTLs are able
to discriminate between p53-presenting tumor cells and
normal tissue, indicating that widely expressed autologous
moleculessuch as p53can serveasa target forCTL-mediated
immunotherapy of tumors [17].
In humans, spontaneous MHC class I restricted p53-
speciﬁc CTL [18, 19], MHC class II restricted p53-speciﬁc
proliferating Th cells [20, 21], and p53 antibody responses
have been observed [22, 23]. Furthermore, several naturally
processed human wild-type p53-derived epitopes in both
MHC class I and MHC class II have been identiﬁed [17].
The presence of cellular and humoral immune responses
against p53 shows that tolerance is not complete for this self-
antigen. In particular CD4 T cell tolerance, based on mouse
observations, is far from profound [24].
On the basis of these preclinical results, which indicate
the occurrence of p53-directed immune responses in cancer
patients, several clinical trials have been performed with vac-
cines targeting p53. These studies have, however, generally
not yet evolved past phase I/II studies.
In this paper the immunogenicity and clinical eﬃcacy
of p53-speciﬁc active immunotherapy in human cancer is
evaluated to assess the potential of this treatment modality
for cancer. Furthermore, we propose a few straightforward
clinically applicable combination strategies to improve clini-
cal eﬃcacy of p53-directed immunotherapies.
2.ClinicalTrialsofp53 PeptideCancerVaccine
Several phase I/II immunization trials using p53 immuno-
gens have been conducted so far (Table 1). We have
summarized the observed immune and clinical responses
in cancer patients, induced by the p53-vaccine (Table 2).
Next, we provide a more detailed account of the studies,
categorized by the diﬀerent vaccination strategies.
2.1. Viral Vector-Based Vaccines. Viral vectors encoding
recombinant transgenes for TAAs (such as p53) capable
of infecting host cells can elicit a tumor-speciﬁc immune
response against the transgene product. Recombinant viral
vector-vaccines encoding full-length TAA may contain epi-
topes for both CD4+ T-helper (Th) cells and CD8+ cyto-
toxic T-lymphocytes (CTLs). The clinical advantage of this
vaccination strategy therefore is that the MHC type of the
individual patient does not need to be considered (reviewed
in [37–40]). Several clinical studies on viral vector-based
vaccines encoding p53 have been conducted.
In a pilot study, Kuball et al. immunized six advanced
stage cancer patients with a recombinant replication-
defective adenoviral vector encoding human full-length
wild-type p53 [25]. Neither tumor responses nor anti-p53
responses were observed; however, all patients showed an
adenoviral immune response. This strong anti-adenoviral-
speciﬁc response may have competed out the p53-speciﬁc
response. Clinical tumor responses were assessed by imaging
diagnostics using National Cancer Instituteresponse criteria.
Three months after initial immunization, 4 patients had
stable disease. After followup of 7–16 months only one
patient had stable disease.
Basedonpreclinicalresultsinmiceandrhesus macaques,
Menon et al. performed a phase I/II clinical study involving
vaccination of end-stage colorectal cancer patients with
a recombinant canarypox virus (ALVAC) encoding wild-
type p53 [26, 27]. Patients were immunized intravenously
with an increasing dosage of ALVAC-p53. From this study, it
appeared that this modality is safe and capableofstimulating
p53-speciﬁc Th1 (IFN-γ) responses in several of these
patients. One out of 16 patients showed stable disease for
a short period of time after immunization with the highest
dose. Fever was the only vaccine-related adverse event. The
authorsconcludefromthistrialthatrepeatedimmunizations
are probably necessary to obtain good clinical responses.
Again, antivector responses were observed in all patients
after vaccination which, by antigenic competition, may have
prevented robust anti-p53 immune responses.
Ina phaseI/IIstudy,Antonia etal.testeda cancervaccine
consisting of dendritic cells transduced with the full-length
wild-type p53 gene delivered via an adenoviral vector [28].
Signiﬁcant p53-speciﬁc T cell responses to vaccination was
found in 13 out of 25 patients (52%) in IFN-γ ELISPOT
assays. In 7outof12HLA-A2positivepatients,an increasein
frequency of CD8+ T cells that secrete IFN-γ in response to
targets pulsed with an HLA-A2 restricted p53 peptide were
found. Four out of 10 patients with a detectable preimmu-
nization level of anti-p53 antibody developed a positive p53-
speciﬁc T cell response to vaccination. No link was found
between the presence of CD4+FoxP3+ regulatory T cells
(Tregs) and p53-speciﬁc T cell responses to vaccination in
the patient’s blood before or after vaccination, despite the
assumption that Tregs downregulate the antitumor immune
response. Objective clinical responses were observed inJournal of Biomedicine and Biotechnology 3
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61.9% of 21 patients treated with second-line chemotherapy
directly after immunization. This result provides direct
clinical evidence that cancer vaccines may be most eﬀective
not as a single modality, but rather in a close combination
with othermethods oftreatment, speciﬁcally, chemotherapy.
This observed eﬀect could be explained by a number of
potential mechanisms, such as down-regulation of the eﬀect
of tumor-produced immunosuppressive factors that prevent
CTLs from killing tumor cells by chemotherapy [41], or
up-regulation of p53 in tumor cells, which can make them
more susceptible to recognition by CTLs [42], or lastly,
chemotherapy may make tumor cells more susceptible to
the cytotoxic eﬀect of CTLs through a perforin-independent
increase in permeability to granzyme B released by the CTLs
[43].
Collectively, viral vector-based vaccines encoding p53
are well tolerated in early-phase clinical trials with minimal
toxicity. Limited p53-speciﬁc immune responses might be
due to antigen competition, as all patients had strong
antivector responses. Future studies on viral vector-based
vaccines should focus on the use of prime-boost strategies
withdiﬀerentvectorsdeliveringp53.Thisstrategyovercomes
the antigenic competition in priming with viral vectors.
Viral vector recombinant Semliki Forest virus, which is not
strongly aﬀected by vector-neutralising antibodies therefore,
has exquisite potency in homologous prime-boost immu-
nization regimens [44].
2.2. Dendritic Cell-Based Vaccines. It is important to inves-
tigate the character of the p53-speciﬁc T cell responses,
because p53-based vaccination of patients should be aimed
at boosting only the desired Th1-type immunity, while stim-
ulation of Th2-type or Tregs should be avoided [45]. This
ﬁnding wouldargueinfavourofapplicationofap53-speciﬁc
vaccination using a delivery mode speciﬁcally stimulating
the anti p53 (CTL) and Th1 responses. Autologousdendritic
cells (DC) expressing the antigen of interest could be one
of these ways (reviewed in [46–48]). Dendritic cells are
highly potent professional antigen-presenting cells (APCs).
Therefore, antitumor vaccines have been designed, using
DCs generated on clinical scale loaded with synthetic MHC
binding peptides known to stimulate peptide-speciﬁc CTLs,
like p53.
Svane et al. reported on their phase I immunization
study in breast cancer patients with p53 peptide pulsed DC
[29]. Autologousdendritic cells were pulsed with three wild-
type and three modiﬁed HLA-A2 restricted p53 peptides
combined with an MHC class II binding peptide (PADRE).
Patients received ten subcutaneous immunizations with at
least 5 × 106 peptide-pulsed dendritic cells combined with
6mIU/m 2 interleukin 2 (IL-2). Two out of six patients had a
clinical response and three out of six developed p53-speciﬁc
T cell responses (including the two patients with a clinical
response), without signiﬁcant toxicity.
The phase II study performed by Svane et al. [30]w a s
carried outin directcontinuation of theirphase Istudy using
the same vaccination regime as described above. Only ﬁve
out of 26 patients completed all ten planned immunizations
due to rapid progression of disease or death. Positive
immunohistochemical staining of p53 by the primary tumor
was found more frequently in patients achieving stable
disease during treatment, indicating an eﬀect of p53-speciﬁc
immune therapy. However, immunohistochemical staining
for p53 might underestimate the patients’ ability to present
p53 at its tumor cell surface, as tumors in which p53
is inactivated indirectly through binding to viral proteins
for example, will not score positive for p53, but can be
recognized by CTLs [1, 2]. In most cases, an increase in
the number of p53-speciﬁc CTLs during vaccination was
measured; however, a tendency towards a more marked
decline at late time points after vaccination was observed.
However, these heavily pretreated metastatic breast cancer
patients with a high tumor burden are not the ideal patient
group to translate p53-speciﬁc activation of the immune
system into signiﬁcant tumor regression.
Dendriticcell-based vaccinesarelaboriousinproduction
and restricted to individual patients, but have the advantage
thatDCsarehighlyeﬃcientAPCs[49].Asigniﬁcant fraction
of the advanced stage breast cancer patients obtained disease
stabilization and induction of p53-speciﬁc immunity during
p53-DC vaccination. Type and maturation status of DCs are
issues to be solved in future studies with this vaccination
approach. Moreover, further clinical studies should be
performed at an earlier stage ofdisease with progression-free
survival or overall survival as an endpoint.
2.3. Peptide-Based Vaccines
2.3.1.ShortPeptides. Sincetheﬁrst identiﬁcationofadeﬁned
tumor-speciﬁc CTL epitope, the concept of immunizing
cancer patients with a single synthetic peptide epitope has
been elaborated (reviewed in [50–52]). The relatively poor
immunogenicity of peptide epitopes requires them to be
injected together with adjuvants. Important advantages of
short peptide vaccination are its deﬁned nature and easy
manner to synthesize.
Lomas et al. performed a phase I trial targeting sev-
eral p53-overexpressing solid cancer types in 14 patients
with an idiotypic vaccine, composed of a pool of eight
peptides derived from the complementarity determining
regions (CDRs) of human anti-p53 antibodies admixed with
granulocyte-macrophage colony-stimulating factor (GM-
CSF) [31]. None of the trial patients was found to have
vaccine-speciﬁc, IFN-γ-secreting T cells as assessed by
ELISPOT assay. However, a vaccine-induced response was
observed in 2 out of 6 patients in the proliferation assay.
Clinical responses were not registered and only CTC I/II
toxicities were observed.
Rahma et al. compared subcutaneous wild-type p53
epitope (264–272) vaccination with intravenous peptide-
pulsed DC administration in 21 ovarian cancer patients
combinedwith IL-2adjuvant in arandomised phase IIstudy.
IL-2 administration resulted in directly induced expansion
of Tregs and in grade II/IV adverse events in both arms of
the study, which was thereafter omitted from the regimen for
these patients [32–34]. P53-speciﬁc T cells were observed in
approximately 70% of patients, irrespective of whether short
peptides or peptide-pulsed DCs were used.6 Journal of Biomedicine and Biotechnology
Recent insights in short peptide vaccination have indi-
cated that vaccination with short exact MHC class I binding
peptides dissolved in chemical adjuvants, in contrast to
peptide-pulsed DCs, is suboptimal mainly because short
peptides load exogenously onto MHC class I molecules,
including those of nonprofessional antigen-presenting cells
[53].
2.3.2. Long Peptides. Another vaccination strategy is the
use of long peptides encoding the whole p53 protein. The
advantage of using long peptides is that if delivered in the
appropriate adjuvant (with APC stimulatory capacity), all
potential MHC class I and MHC class II epitopes within the
delivered peptides will be processed and presented to host
T cells. These long peptide vaccines are independent of
MHC-binding motif prediction or processing algorithms
and can be administered to subjects independent of their
MHC type (reviewed in [53]).
A phase I/II trial using wild-type p53-derived synthetic
long peptides (SLP) in ovarian cancer was performed by
Leﬀers et al. [35]. Twenty patients with recurrent elevation
of CA-125 were included and immunized with 10 overlap-
ping p53-SLP in Montanide ISA51. IFN-γ producing p53-
speciﬁc T cell responses were induced in all patients who
completed the vaccination-scheme as measured by IFN-γ
ELISPOT. Vaccine-induced p53-speciﬁc T cells are mediated
predominantly by Th2-cells as determined by cytokine bead
array and are capable of migration into immunization sites.
The number of Tregs remained constant before and after
immunization. Stable disease was observed in 2 out of
20 patients, although no relationship was determined with
vaccine-induced immunity.
Speetjens et al. used the same p53-SLP vaccine (Leﬀers
et al.) in a phase I/II trial, vaccinating ten metastatic
colorectal cancer patients [36]. P53-speciﬁc T cells isolated
from the vaccination site were characterised as Th cells
which displayed a mixed T-helper 1 and 2 cytokine proﬁle
with varying percentages of IFN- and IL-2 producing p53-
speciﬁc T cells as determined by cytokine bead array. No
overt induction of p53-speciﬁc Tregs after p53-vaccination
was found. Furthermore, in 6 out of 9 patients, strong
proliferative p53-speciﬁc T cell responses were observed in
blood samples taken ∼6 months after the last vaccination.
Peptide based-vaccines have the advantage that antigen-
speciﬁc immune responses can be easily monitored as a tool
toimprovethevaccineorvaccinationstrategy[52].However,
vaccination with short peptides is far from optimal because
it can lead to immunological tolerance of the immunizing
antigens because T and B cells, in contrast to properly
activated DC, lack the costimulatory surface molecules
required for appropriate eﬀector CTL generation [54–58].
Inaddition, immunizations with short-peptide vaccinesmay
induce outgrowth of antigen loss variants of the tumor [59].
Furthermore, a single peptide epitope induces either Th
cells or CTL and responses to such epitopes are limited to
patients with speciﬁc MHC types capable of presenting the
peptide used [53]. Limited humoral, cellular and clinical
responses were shown in patients immunized by short-
peptide vaccines.
In contrast, IFN-γ producing p53-speciﬁc T cell re-
sponses were induced in the majority of patients receiving
long-peptide vaccination. This is probably attributable to
the fact that the T cell epitopes in the long peptide vaccine
are eﬃciently processed and presented by dendritic cells and
that the response induced by this vaccine is not restricted to
one MHC type. Despite the induction of p53-speciﬁc T cell
immunity in vaccinated patients, the p53 long peptide vac-
cines so far have not induced clinical eﬃcacy. Long peptide
vaccines targeting p53, therefore, should be combined with
other forms of treatment to eliminate potential mechanisms
of immune failure.
3.Perspectives
Thus far, p53-targeting therapeutic vaccination strategies
in cancer patients including administration of recombinant
viral vectors, peptide pulsed dendritic cells, short peptide
and long peptide vaccines have not shown consistent and/or
convincing clinical eﬃcacy.
Whereas some of these vaccines, in particular viral
vectors and short peptides, have intrinsic shortcomings,
a likely explanation for the lack of eﬃcacy is that, despite
induction of p53-speciﬁc CD4+ T-helper (Th) cells and the
recruitment of CD8+ cytotoxic T-lymphocytes (CTLs) to the
tumor, a robust antitumor response is not accomplished due
to immunoregulatory mechanisms counteracting eﬀective
T cell-mediated tumor cell killing. T cells that eﬀectively
home to tumor metastases can be dysfunctional, point-
ing toward immunosuppressive mechanisms in the tumor
microenvironment [60]. T cell anergy due to insuﬃcient B7
costimulation, extrinsic suppression by regulatory myeloid
and regulatory T cell populations, inhibition by ligands such
as programmed death ligand-1, metabolic dysregulation
by enzymes such as indoleamine-2,3-dioxygenase, and the
action of inhibitory factors such as TGF-β have all been
implicated in the lack of eﬃcacy [45, 61].
Because of the disappointing clinical results induced by
the p53-vaccines, we can conclude that the immunogenicity
of these vaccines needs to be enhanced by improving the
robustness of the induced eﬀector T cell responses and by
eﬀectively disrupting the counterproductive immunoregu-
lation [62] .I tm a ya l s ob eu s e f u lt os i m u l t a n e o u s l yt a r g e t
additional tumor antigens [63]. Below we discuss several
straightforward clinically applicable methods that have been
proposed to augment immunogenicity and clinical eﬃcacy
of immunotherapeutic vaccines.
3.1. Eliminating Regulatory T Cells by Cyclophosphamide.
As mentioned above, the observed lack of clinical eﬃcacy
may be partly attributed to the presence of CD4+FoxP3+
regulatory T cells (Tregs). It is becoming apparent that
immunotherapyitselfcaninduceand/orboostTregs andthat
these vaccine-induced Tregs are associated with treatment
failure [64–68]. Immunosuppression mediated by Tregs is
a major hurdle for successful tumor immunotherapy as
Tregs suppress antigen-speciﬁc T cell responses [60, 65–
67]. Strategies to eliminate or suppress Tregs to improve
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with commonly used chemotherapeutic agents, such as
cyclophosphamide,ﬂudarabine,orCOX-2inhibitors,nextto
direct targeting of Tregs by monoclonal antibodies [69–76].
Low-dose cyclophosphamide is easy to incorporate into
aclinicalsetting. Dosagesofcyclophosphamideused incom-
bination with immunotherapy are generally insuﬃcient for
cytotoxic reductions of tumor burden, but reduce numbers
of Tregs and impair their functionality without deleting
other immune cells [69, 77–79]. Furthermore, a cohort
study in metastatic pancreatic cancer showed an enhanced
induction of antigen-speciﬁc T cells in patients pretreated
with cyclophosphamide compared to patients who were
notpretreatedwith cyclophosphamide.Additionally,median
overall survival of patients treated with cyclophosphamide
was almost twice as high as that of patients who did
not receive cyclophosphamide. This was similar to results
obtained with second-line therapy for metastatic pancreatic
cancer [80]. Although the number of circulating Tregs in
the patient group vaccinated with the p53-SLP by Leﬀers et
al. is relatively low (7.0%), their presence and recruitment
to the tumor may nevertheless foster tolerance to the
tumor. We have started a new clinical trial in which p53-
SLP immunization is combined with low-dose cyclophos-
phamide to test whether this increases immunity and clinical
activity.
3.2. Immunopotentiation by Anti-CTLA-4. Another immu-
nopotentiation strategy that has been used in the clinical
setting is blockade of cytotoxic T-lymphocyte antigen-4
(CTLA-4) aiming to counteract inhibitory signals in order
to induce antitumor immunity. CTLA-4 is a costimulatory
molecule expressed on activated T cells that delivers an
inhibitory signal which reverses the T cell response, result-
ing in anergy [81]. Two human anti-CTLA-4 monoclonal
antibodies(mAbs),MDX-010(ipilimumab)and CP-675,206
(tremelimumab), have thus far been used in clinical trials
with encouraging results in patients with melanoma, lym-
phoma, and urothelial carcinoma of the bladder [74, 82–
85]. Anti-CTLA-4 mAbs are well poised to be combined with
other therapies. Moreover, these antibodies may enhance the
eﬀectiveness of other therapies like cancer vaccines when
used in combination. Therefore, several clinical trials on
antitumor regimens added anti-CTLA-4 to their treatment
regime, aiming to improve clinical eﬃcacy in the participat-
ing patients [86–88].
Anti-CTLA-4 mAbs have shown antitumor activity;
however, accumulating evidence indicates that anti-CTLA-4
mAbs paradoxically increases the number of Tregs, thereby
hampering the eﬀect of anti-CTLA-4 [89]. This has stim-
ulated interest in designing clinical trials using anti-CTLA-
4 mAbs in combination with Treg controlling strategies
to improve clinical outcome. Several promising preclinical
studies combining anti-CTLA-4 with Treg depletion have
been conducted so far [90–92].
The studies of combined immunopotentiating low-dose
cyclophosphamide and anti-CTLA-4 provide the foundation
for integrating immunotherapy with other targeted ther-
apies for the treatment of patients with advanced stage
cancer.
3.3. Immunostimulationby Chemotherapeutic Regimens. The
interaction of tumor cell death due to chemotherapy on
one hand and induction of antitumor immune responses
induced by this cell death on the other hand might be essen-
tial to achieve the optimal result in tumor eradication [93–
95]. It is postulated by Zitvogel et al. that activation of the
calreticulin exposure pathway is an important mechanism
of activation of the immune system after treatment with
classical therapies like chemotherapy [96]. They thought
that chemotherapy in general results in a strong reduction
of major components of the immune system and thereby
harming the immune system ready to attack the tumor does
not hold true anymore. Evolving evidence shows the oppo-
site. Immunotherapy in combination with chemotherapy
might be a very eﬀective strategy as induction of long-lived
antigen-speciﬁc memory T cells recently has been identiﬁed
[97]. Cisplatinum next to paclitaxel and doxorubicin, drugs
often used in gynaecologic malignancies, reportedly make
tumor cells more susceptible to Granzyme B-dependent
killing by cytotoxic T cells [43]. It is attractive to use these
immunomodulatory eﬀects of chemotherapy by combining
it with p53-speciﬁc immunization.
3.4. New Vaccination Strategy: Multi-Epitope Vaccines. Most
clinical studies included in this paper targeted only p53,
limiting the use of such vaccines to those patients with
(over)expression of this speciﬁc tumor antigen. Further-
more, tumor cells might lose antigens and therefore display
a reduced susceptibility to vaccine-induced immunity in the
course of the vaccinations. Immunization using a cocktail
of antigens has been proposed as a “universal” vaccine
strategy [98]. As solid tumors often show heterogeneous
protein expression, multi-antigen vaccines may have greater
therapeutic potential which can compensate for tumor
antigen-loss variants [63, 99]. The ability to target multiple
antigens may also improve the immunogenicity of therapeu-
ticvaccines.Webelievethatadditionofothertumorantigens
to the p53-vaccine might ultimately result in an enhanced
clinical eﬀect [98], particularly because the CTL repertoire
against p53 based on mouse studies and observations in
patients, appears to be more deeply tolerized than the Th cell
repertoire [24].Additionofimmunotherapyagainst antigens
that more readily elicit tumoricidal CTL responses may
therefore fully exploit the excellent ability of p53 vaccination
to elicit Th cell responses.
Thus far, several clinical trials targeting multi-antigens
have been conducted.Kirkwood et al. reported that the eﬀect
ofamulti-epitopemelanoma vaccine testedin aphase IItrial
iscorrelatedwithprolongedsurvivalinmetastaticmelanoma
patients. Addition of immunomodulatory cytokines had no
beneﬁcial eﬀect on prognosis [100]. A multi-antigen vaccine
tested in prostate cancer patients resulted in a long-term
stable disease [101].
Recently, a p53 comprising multi-epitope vaccine has
been administered to malignant melanoma patients in
a phase I/II clinical trial. Results of the DC-vaccine pulsed
with p53, survivin and telomerase-derived peptides in
combination with low-dose IL-2, have been published by
Trepkiakas et al. [102]. This group previously targeted p538 Journal of Biomedicine and Biotechnology
in a DC vaccination trial as described in this paper [29, 30].
Due to this new multi-antigen pulsed DC-vaccine, sta-
ble disease correlated with prolonged survival suggesting
a clinical beneﬁt. Nevertheless, signiﬁcant changes in Treg
frequencies during treatment were seen and ascribed to
IL-2 administration. Consequently, IL-2 was removed from
their DC vaccination strategy and replaced by low-dose
cyclophosphamide in an ongoing clinical trial in melanoma
patients in order to enhance the immune and clinical
responses.
Addition of multiple antigens in an immunotherapeutic
vaccinewillenhancethebarrier against escapeofantigenloss
variants of the tumor and will exploit more fully the antitu-
mor CTL potential of the patient. Future studies on multi-
epitope immunotherapy, moreover applicable in a higher
percentageofpatients,are expectedtoresultina signiﬁcantly
enhanced eﬃcacy of anticancer immunotherapy.
4.Conclusion
Over the past decade, several studies on p53-vaccines for
immunotherapeutic treatment of cancer patients have been
conducted. Diﬀerent vaccination strategies varying from
viral vectors, dendritic cells, and short and long peptides
havebeenused. Ofthesevaccination modalities, viral vectors
and short peptides suﬀer from major drawbacks. Although
peptide-loaded DC and long peptides have induced reason-
ably strong p53-speciﬁc immune responses, in particular
CD4+ T cell responses, robust clinical responses so far
have failed to materialize. In this paper, we point out that
the limited clinical eﬃcacy dictates further exploration of
new immunization strategies. P53-vaccines can easily be
combined with low-dose cyclophosphamide, anti-CTLA-4,
chemotherapeutic regimens, or other tumor antigens, as
immunopotentiation treatment modalities. An integrative
immunotherapeutic strategy combining “up-front” Treg cell
ablation followed by p53vaccination may limit generationof
newtumor-sensitized Tregs andtherefore,might improvethe
clinical responses in cancer patients. Moreover, addition of
multiple antigens to the p53-vaccine will make it applicable
in a higher percentage of patients and will exploit the
anticancer T cell response. Future studies will be needed to
establish the best combination of therapy and to identify
cancer patients most likely to respond to combined anti-p53
therapies.
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